BMSN. Is this good or bad.
BMSN is my must see new pick!
This subpenny could hit a penny Wednesday!
Hello Traders!
A lot of biotech plays are really lightweights dressed up in heavyweight clothing – just imagine Manny Pacquiáo trying to pass himself off as Mike Tyson.
BMSN on the other hand is different, night and day different.
Last time I introduced a company like this it soared triple digits. I have the same confidence here when it comes to BMSN. Don't be surprised if BMSN blows through a penny Wednesday, which would represent a gain of 233%.
Introducing BMSN which closed Tuesday at .003
This biotech dynamo is a massive player in the research and development of cutting edge drugs and therapies and has a strong presence in the $32 billion a year stem cell research industry.
As a result of this very broad and potent profile, BMSN attracts very strong investor attention. Average volume in BMSN is a staggering 27 million+ shares and so when the gain potential presents itself, it is absolutely huge.
How huge?
Right now based on the massively undervalued valuation of BMSN, investors can lock up gain potential of more than 450%.
Wall Street has been taking note too and since December last year more than 1400% has been added to lower valuations.
In other words, BMSN is on the move and all the indicators suggest that the pace will get a shot of adrenaline soon.
Biotech opportunities as real as BMSN don’t come along often so don’t hesitate to make a move on this one.
The sooner you complete your research the quicker you can get in on the action.
Investor Highlights
BMSN has added more than 1400% to its 52-week low of 0.0002 since December last year.
BMSN has a RSI of 45 and is trading on a solid volume growth curve.
BMSN has seen strong movement in several of its key moving averages, including its 200-day MA which is up 383%
BMSN has entered into a license agreement for the development of vaccines using ddRNAi gene silencing technology. This is expected to increase the company’s growth potential in the near and medium terms.
BMSN now has strong strategic footing in the RNAi industry courtesy of its appointment of Dr. David Suhy, a pioneer in the field of RNA Interference (RNAi). Dr Suhy will lend his expertise as a member of BMSN’s strategic advisory board.
BMSN is well placed in the stem cell products industry which was worth more than $4.6 billion in 2012.
BMSN through its subsidiary Regen BioPharma, is busy wrapping up patent applications in support of its Investigational New Drug (IND) application (#15376) with the U. S. Food and Drug Administration (FDA).
BMSN is a massive player the development of cancer gene silencing technology, a presence which exposes the company to and industry with more than $70 billion a year in revenues.
About BMSN
BMSN (Bio-Matrix Scientific Group Inc.) is a biotechnology research and development company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories.
BMSN is pursuing relationships with hospitals, medical institutes, research firms and biotechnology companies to assist in stem cell research, cell culturing and Regenerative Medicine therapies.
BMSN’s facilities are available for processing, culturing and storage of specimens. Also, under certain situations, the Company has laboratories available to organizations conducting research.
BMSN to Benefit from Strong Stem Cell Market Outlook
A new report by Visiongain predicts that the overall world market for stem cell technologies in medicine will reach $7.3 billion for 2014. That market will be stimulated by new treatments and increasing use of related products in drug development. Those findings appear in Stem Cell Technologies: World Market Outlook 2012-2022, published in May 2012. Visiongain is a business information provider based in London, UK.
Visiongain forecasts that the stem cells market will expand rapidly from 2012 to 2022, achieving multi-billion-dollar revenues worldwide. More than 200 companies operate in that field. The next ten years will result in many new medical products and uses for stem cells. The period to 2022 will establish the foundations of a therapeutic revolution, the report concludes.
Haematopoietic stem cell transplantation is an established treatment for blood cancers. Revenues from transplants of bone marrow, peripheral blood and umbilical cord blood form much of the market in 2012.
Banking of umbilical cord blood (other stem cell-containing blood units) and culturing and processing of stem cells for laboratory work are the other established business areas in 2012. That commercial activity is only the start, the report argues, with stem cell technologies poised for important advances by 2020.
Dr James Evans, a pharmaceutical industry analyst in visiongain, explains: “Stem cell technologies have been hyped for a long time, but it’s only now that we’re going to see the first approved products, treatments based on mesenchymal stem cells or improvements to stem cell transplants.
Stem cell-based innovations are likely in the treatment of vascular diseases, autoimmune diseases, diabetes, dry AMD and other serious disorders. Some of these breakthroughs will be a commercial reality by 2022.
“The use of stem cells in laboratory assays for drug development is a strong opportunity for the biotechnology industry.
Stem cells offer an improved way to model diseases in vitro, identify candidate drugs and perform toxicity testing and other assays. With drug development costs and failures such a concern for the pharmaceutical industry, that segment will be important to the overall stem cells market, representing around a third of its revenues by 2022, our study predicts.”
With BMSN pioneering so many offerings in the stem cell space, its growth potential should benefit immensely from these robust projections. $7.3 billion is an absolutely huge market from which to tap profits and I expect BMSN to do no less.
Recent Developments
Bio-Matrix Scientific Group Recruits RNA Interference Pioneer Dr. David Suhy to Regen BioPharma Inc.'s Scientific Advisor Board
SAN DIEGO, CA--(Marketwired - Sep 17, 2013) - Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) announced that it has recruited, Dr. David Suhy, a pioneer in the field of RNA Interference (RNAi), to join the Scientific Advisory Board of Regen BioPharma Inc. ("Regen"), a subsidiary of Bio-Matrix Scientific Group Inc.
"Dr. Suhy, a pioneer of the RNAi industry, was already developing therapeutic candidates in this field in 2003 before the concept of RNAi was accepted in the scientific community," said David Koos, Chairman & CEO of Regen. "We are excited to apply Dr. Suhy's experience in the development of our RNAi based cancer therapeutic."
Regen's Chief Scientific Officer, Dr. Thomas Ichim, noted, "Dr. David Suhy, senior vice president of research and development at Tacere Therapeutics (a subsidiary of Benitec Biopharma), leads all Tacere's clinical development programs.
He was one of the inventors of TT-034, a novel therapeutic product containing three separate RNAi elements targeted against the Hepatitis C virus, and has directed development of the TT-03x series of compounds which target the Hepatitis C virus (HCV), from the drawing board through to Investigational New Drug (IND) enabling studies."
A spokesperson for the Company provided further insight on RNAi, stating this is a process by which genes may be selectively blocked using a natural mechanism the body normally uses to protect against viruses.
The Nobel Prize in Medicine was awarded to Fire and Mello in 2006 for making this discovery. Benitec has been granted international patents on RNAi which have been licensed to Regen for one specific gene, indolamine 2,3 deoxygenase (IDO), which is associated with cancer's ability to suppress the immune system.
Regen Chief Scientific Officer Dr. Thomas Ichim together with Professor Weiping Min at the University of Western Ontario has successfully treated breast cancer (1) and melanoma (2) in animals using this approach.
"With Regen's background in the field of tumor immunology, their licensed intellectual property from Benitec Biopharma, and clinical expertise, I look forward to assisting the Company in developing their protocols with the end goal being taking this safe and nontoxic cancer therapy to patients," said Dr. Suhy.
BMSN is clearly on the front lines of the fight against cancer and so its gain potential shouldn’t be taken lightly. As I mentioned above, the big push to its 12-month high could yield gain potential of more than 450%. I really like this play.
Start your research right now.
BMSN is my must see new pick!
This subpenny could hit a penny Wednesday!
Hello Traders!
A lot of biotech plays are really lightweights dressed up in heavyweight clothing – just imagine Manny Pacquiáo trying to pass himself off as Mike Tyson.
BMSN on the other hand is different, night and day different.
Last time I introduced a company like this it soared triple digits. I have the same confidence here when it comes to BMSN. Don't be surprised if BMSN blows through a penny Wednesday, which would represent a gain of 233%.
Introducing BMSN which closed Tuesday at .003
This biotech dynamo is a massive player in the research and development of cutting edge drugs and therapies and has a strong presence in the $32 billion a year stem cell research industry.
As a result of this very broad and potent profile, BMSN attracts very strong investor attention. Average volume in BMSN is a staggering 27 million+ shares and so when the gain potential presents itself, it is absolutely huge.
How huge?
Right now based on the massively undervalued valuation of BMSN, investors can lock up gain potential of more than 450%.
Wall Street has been taking note too and since December last year more than 1400% has been added to lower valuations.
In other words, BMSN is on the move and all the indicators suggest that the pace will get a shot of adrenaline soon.
Biotech opportunities as real as BMSN don’t come along often so don’t hesitate to make a move on this one.
The sooner you complete your research the quicker you can get in on the action.
Investor Highlights
BMSN has added more than 1400% to its 52-week low of 0.0002 since December last year.
BMSN has a RSI of 45 and is trading on a solid volume growth curve.
BMSN has seen strong movement in several of its key moving averages, including its 200-day MA which is up 383%
BMSN has entered into a license agreement for the development of vaccines using ddRNAi gene silencing technology. This is expected to increase the company’s growth potential in the near and medium terms.
BMSN now has strong strategic footing in the RNAi industry courtesy of its appointment of Dr. David Suhy, a pioneer in the field of RNA Interference (RNAi). Dr Suhy will lend his expertise as a member of BMSN’s strategic advisory board.
BMSN is well placed in the stem cell products industry which was worth more than $4.6 billion in 2012.
BMSN through its subsidiary Regen BioPharma, is busy wrapping up patent applications in support of its Investigational New Drug (IND) application (#15376) with the U. S. Food and Drug Administration (FDA).
BMSN is a massive player the development of cancer gene silencing technology, a presence which exposes the company to and industry with more than $70 billion a year in revenues.
About BMSN
BMSN (Bio-Matrix Scientific Group Inc.) is a biotechnology research and development company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories.
BMSN is pursuing relationships with hospitals, medical institutes, research firms and biotechnology companies to assist in stem cell research, cell culturing and Regenerative Medicine therapies.
BMSN’s facilities are available for processing, culturing and storage of specimens. Also, under certain situations, the Company has laboratories available to organizations conducting research.
BMSN to Benefit from Strong Stem Cell Market Outlook
A new report by Visiongain predicts that the overall world market for stem cell technologies in medicine will reach $7.3 billion for 2014. That market will be stimulated by new treatments and increasing use of related products in drug development. Those findings appear in Stem Cell Technologies: World Market Outlook 2012-2022, published in May 2012. Visiongain is a business information provider based in London, UK.
Visiongain forecasts that the stem cells market will expand rapidly from 2012 to 2022, achieving multi-billion-dollar revenues worldwide. More than 200 companies operate in that field. The next ten years will result in many new medical products and uses for stem cells. The period to 2022 will establish the foundations of a therapeutic revolution, the report concludes.
Haematopoietic stem cell transplantation is an established treatment for blood cancers. Revenues from transplants of bone marrow, peripheral blood and umbilical cord blood form much of the market in 2012.
Banking of umbilical cord blood (other stem cell-containing blood units) and culturing and processing of stem cells for laboratory work are the other established business areas in 2012. That commercial activity is only the start, the report argues, with stem cell technologies poised for important advances by 2020.
Dr James Evans, a pharmaceutical industry analyst in visiongain, explains: “Stem cell technologies have been hyped for a long time, but it’s only now that we’re going to see the first approved products, treatments based on mesenchymal stem cells or improvements to stem cell transplants.
Stem cell-based innovations are likely in the treatment of vascular diseases, autoimmune diseases, diabetes, dry AMD and other serious disorders. Some of these breakthroughs will be a commercial reality by 2022.
“The use of stem cells in laboratory assays for drug development is a strong opportunity for the biotechnology industry.
Stem cells offer an improved way to model diseases in vitro, identify candidate drugs and perform toxicity testing and other assays. With drug development costs and failures such a concern for the pharmaceutical industry, that segment will be important to the overall stem cells market, representing around a third of its revenues by 2022, our study predicts.”
With BMSN pioneering so many offerings in the stem cell space, its growth potential should benefit immensely from these robust projections. $7.3 billion is an absolutely huge market from which to tap profits and I expect BMSN to do no less.
Recent Developments
Bio-Matrix Scientific Group Recruits RNA Interference Pioneer Dr. David Suhy to Regen BioPharma Inc.'s Scientific Advisor Board
SAN DIEGO, CA--(Marketwired - Sep 17, 2013) - Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) announced that it has recruited, Dr. David Suhy, a pioneer in the field of RNA Interference (RNAi), to join the Scientific Advisory Board of Regen BioPharma Inc. ("Regen"), a subsidiary of Bio-Matrix Scientific Group Inc.
"Dr. Suhy, a pioneer of the RNAi industry, was already developing therapeutic candidates in this field in 2003 before the concept of RNAi was accepted in the scientific community," said David Koos, Chairman & CEO of Regen. "We are excited to apply Dr. Suhy's experience in the development of our RNAi based cancer therapeutic."
Regen's Chief Scientific Officer, Dr. Thomas Ichim, noted, "Dr. David Suhy, senior vice president of research and development at Tacere Therapeutics (a subsidiary of Benitec Biopharma), leads all Tacere's clinical development programs.
He was one of the inventors of TT-034, a novel therapeutic product containing three separate RNAi elements targeted against the Hepatitis C virus, and has directed development of the TT-03x series of compounds which target the Hepatitis C virus (HCV), from the drawing board through to Investigational New Drug (IND) enabling studies."
A spokesperson for the Company provided further insight on RNAi, stating this is a process by which genes may be selectively blocked using a natural mechanism the body normally uses to protect against viruses.
The Nobel Prize in Medicine was awarded to Fire and Mello in 2006 for making this discovery. Benitec has been granted international patents on RNAi which have been licensed to Regen for one specific gene, indolamine 2,3 deoxygenase (IDO), which is associated with cancer's ability to suppress the immune system.
Regen Chief Scientific Officer Dr. Thomas Ichim together with Professor Weiping Min at the University of Western Ontario has successfully treated breast cancer (1) and melanoma (2) in animals using this approach.
"With Regen's background in the field of tumor immunology, their licensed intellectual property from Benitec Biopharma, and clinical expertise, I look forward to assisting the Company in developing their protocols with the end goal being taking this safe and nontoxic cancer therapy to patients," said Dr. Suhy.
BMSN is clearly on the front lines of the fight against cancer and so its gain potential shouldn’t be taken lightly. As I mentioned above, the big push to its 12-month high could yield gain potential of more than 450%. I really like this play.
Start your research right now.
